Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.

MLA

van Kempen, Zoé L. E., et al. “Personalized Extended Interval Dosing of Natalizumab in MS: A Prospective Multicenter Trial.” Neurology, vol. 95, no. 6, Aug. 2020, pp. e745–54. EBSCOhost, https://doi.org/10.1212/WNL.0000000000009995.

APA

van Kempen, Z. L. E., Hoogervorst, E. L. J., Wattjes, M. P., Kalkers, N. F., Mostert, J. P., Lissenberg-Witte, B. I., de Vries, A., Ten Brinke, A., van Oosten, B. W., Barkhof, F., Teunissen, C. E., Uitdehaag, B. M. J., Rispens, T., & Killestein, J. (2020). Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. Neurology, 95(6), e745–e754. https://doi.org/10.1212/WNL.0000000000009995

Chicago

van Kempen, Zoé L E, Erwin L J Hoogervorst, Mike P Wattjes, Nynke F Kalkers, Jop P Mostert, Birgit I Lissenberg-Witte, Annick de Vries, et al. 2020. “Personalized Extended Interval Dosing of Natalizumab in MS: A Prospective Multicenter Trial.” Neurology 95 (6): e745–54. doi:10.1212/WNL.0000000000009995.